source
- AbbVie’s HS drug lutikizumab meets Phase 3 goal but falls short of analyst expectationsAbbVie reported that its investigational IL‑1α/β inhibitor lutikizumab achieved the primary endpoint in the Phase 3 INTREPID study for hidradenitis suppurativa, a chronic inflammatory skin disease…
- FDA approves GSK hepatitis B drug; EQT to acquire Qiagen for $10.8 billionThe U.S. Food and Drug Administration has granted approval to GlaxoSmithKline's new hepatitis B therapy, marking a regulatory milestone for the company. Private-equity firm EQT announced a definit…